12:00 AM
 | 
Mar 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Rencarex girentuximab: Phase III ongoing

Wilex said FDA approved the company's plans to skip a planned interim analysis and proceed directly to the final analysis in the double-blind, placebo-controlled Phase III ARISER trial of Rencarex to treat ccRCC. In December, the company said a decline in the trial's rate of recurrence over the past year led an IDMC to conclude that the trial is mature enough to conduct the...

Read the full 296 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >